We performed extensive phenotyping, including body composition, insulin sensitivity with euglycemic clamps, glucose tolerance with oral glucose load, metabolic risk factors, and cytokines, and transcriptomic analysis in liver biopsies from 58 individuals with or without a diagnosis of NAFLD and NASH. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.